Human PD-L1 Nanobody For Immuno-PET Imaging: Sites-pecific Radiolabeling Strategies

Jessica Bridoux, Katrijn Broos, Quentin Lecocq, Maxine Crauwels, Charlotte Martin, Frederik Cleeren, Mikhail Kondrashov, Steven Ballet, G. Bormans, Magnus Schou, Chad Elmore, Geert Raes, Serge Muyldermans, Nick Devoogdt, Marleen Keyaerts, Vicky Caveliers, Catarina Xavier

Research output: Unpublished contribution to conferencePoster

Abstract

Nanobodies (Nbs) are ideal probes for positron emission tomography (PET) imaging and can be radiolabeled with short-lived radioisotopes such as gallium- 68 (68Ga) or fluorine-18 (18F). In this study, we aim to develop a site-specifically radiolabeled human PD-L1 (hPD-L1) Nb for non-invasive characterization of whole body PD-L1 expression. A site-specific functionalization technique of Nbs involves the use of the Sortase A enzyme. The lead hPD-L1 Nb is engineered with the LPETG motif at its C-terminus, allowing recognition of the enzyme. Tris-glycine peptides, used as nucleophilic probes in the Sortase-mediated ligation, are synthesized to contain the NOTA or the RESCA chelator for direct labeling under mild conditions with 68Ga or [18F]Al-F respectively. Peptides containing unsaturated moieties such as azide (N3) or tetrazine (Tz) functions can also be introduced for indirect labeling via copper-free click chemistry with 18F-labeled DBCO or BCN prosthetic groups. This functionalization strategy allowed to obtain the hPD-L1 Nb coupled to NOTA or RESCA chelator, azide (N3) or tetrazine (Tz) function with high purity (≥99%) and in high yields (52% - 63%). Functionalization did not affect affinity nor specificity. 68Ga labeling of NOTA-(hPD-L1) was performed in 10 min in 80% decay-corrected radiochemical yield (DC-RCY), ≥99% radiochemical purity (RCP) and apparent molar specific activity of 85 GBq/μmol. In vivo targeting revealed high tumour uptake and no unspecific organ uptake, except in kidneys and bladder because of excretion. [18F]Al-F labeling of RESCA-(hPD-L1) was performed at R.T. in 12 min in a 29% DC-RCY and with a RCP > 99%. First attempts to label Tz- (hPD-L1) with [18F]F-PEG3-BCN showed about 30% conversion after 10 minutes, and labeling conditions still require optimization. The most promising strategy in terms of ease of synthesis and in vivo behaviour will be selected for future clinical translation of the hPD-L1 Nb. Acknowledgments: This project is funded by the EU-H2020-MSCA-ITN-PET3D.
Original languageEnglish
Publication statusPublished - 18 Oct 2019
EventORC-day 2019 - UZ Brussel (To be confirmed), Jette, Belgium
Duration: 18 Oct 201918 Oct 2019
https://orc.vub.be/event/it-seminar/

Conference

ConferenceORC-day 2019
Country/TerritoryBelgium
CityJette
Period18/10/1918/10/19
Internet address

Fingerprint

Dive into the research topics of 'Human PD-L1 Nanobody For Immuno-PET Imaging: Sites-pecific Radiolabeling Strategies'. Together they form a unique fingerprint.

Cite this